## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($317.33)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Amgen adds preclinical cancer asset via $840M deal for Dark Blue Therapeutics**
- Source: FirstWord Pharma | 20260106T151839 | Bullish | Relevance: 100%
- Amgen has acquired Dark Blue Therapeutics for $840 million, gaining a preclinical cancer asset. This move expands Amgen's oncology pipeline with a new potential therapeutic target.

**2. Amgen Acquires Privately-held Dark Blue Therapeutics In $840 Mln Deal**
- Source: Nasdaq | 20260106T143038 | Bullish | Relevance: 100%
- Amgen, Inc. (AMGN) has acquired UK-based Dark Blue Therapeutics Ltd. in a deal worth up to $840 million. This acquisition adds an investigational small molecule to Amgen's portfolio, targeting proteins (MLLT1/3) that drive specific types of acute myeloid leukemia (AML). Preclinical data suggests promising anti-cancer activity for this new therapy, which will strengthen Amgen's early oncology discovery efforts.

**3. Zenasâ€™s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival**
- Source: Citeline News & Insights | 20260106T141538 | Somewhat-Bearish | Relevance: 100%
- Zenas BioPharma announced that its investigational drug obexelimab met its primary endpoint in a Phase III trial for IgG4-related disease (IgG4-RD). While the drug demonstrated efficacy, it appears to trail Amgen's rival treatment in certain aspects. The company is positioning obexelimab as a potentially safer option compared to other existing treatments like Ocrevus and Kesimpta.

**4. Amgen buys UK biotech in deal worth up to $840M to target blood cancer**
- Source: Stock Titan | 20260106T140136 | Bullish | Relevance: 100%
- Amgen (NASDAQ: AMGN) has acquired UK-based Dark Blue Therapeutics for up to $840 million, expanding its oncology pipeline with an investigational small molecule targeting specific types of acute myeloid leukemia (AML). Preclinical data show promising anti-cancer activity for the MLLT1/3 protein degrader. The acquisition aims to strengthen Amgen's early oncology discovery and accelerate the program toward clinical investigation.

**5. What to Expect From Amgen's Q4 2025 Earnings Report**
- Source: Barchart.com | 20260106T120739 | Bullish | Relevance: 100%
- Amgen Inc. (AMGN) is anticipated to announce its fiscal fourth-quarter 2025 earnings soon, with analysts expecting a diluted profit of $4.74 per share, a decrease from the year-ago quarter but with a history of surpassing EPS estimates. The company's stock has outperformed the S&P 500 and the Health Care Select Sector SPDR Fund over the past 52 weeks, driven by strong demand for its newer medicines and a diversified portfolio. Analysts maintain a "Moderate Buy" rating for AMGN, projecting a slight upside from current levels.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Forward P/E 15.0x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $177.8B |
| Beta | 0.45 |
| 52W Range | $259.35 - $346.38 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 15.0 |
| Current P/E | 15.5 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.5% over 5 days). Below STRENGTH zone by 3.4pp (needs >4.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.52), momentum weakening. RSI neutral at 53. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.64% (CS: 46) | Neutral |
| RSI_14 | 53.1 | Neutral |
| MACD Histogram | -0.52 | Bearish |
| vs SMA20 | 1.014x | Above |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 1.108x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $330.17
- **Stop Loss:** $317.33 (3.9% risk)
- **Target:** $355.85 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $33,677.34
- **Portfolio %:** 33.68%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*